Hormone replacement therapy does not increase thrombosis risk following THA: a national database study

Journal of Experimental Orthopaedics

Table 2 Patient demographics and comorbidities

		HRT (n = 3,936)	Control (n = 39,360)	OR	95% CI	P
Age	40–44	253	2426	1.05	0.91 – 1.20	0.5118
	45–49	443	4490	0.98	0.89 – 1.09	0.7741
	50–54	719	7031	1.03	0.94 – 1.12	0.5285
	55–59	858	8344	1.04	0.96 – 1.12	0.3807
	60–64	812	7911	1.03	0.95 – 1.12	0.4284
	65–69	572	5667	1.01	0.92 – 1.11	0.8186
	70–74	408	3916	1.05	0.94 – 1.17	0.4059
	75–79	151	1450	1.04	0.88 – 1.24	0.6290
	80 +	14	158	0.89	0.51 – 1.53	0.6638
Hypertension		1860	19,558	0.91	0.85—0.97	0.0036
Tobacco Use Disorder		653	7617	0.83	0.76—0.90	< 0.0001
Alcohol Use Disorder		84	843	1.00	0.79—1.25	0.9749
Diabetes Mellitus		583	6431	0.89	0.81—0.98	0.0132
Chronic Kidney Disease		122	1385	0.88	0.73—1.06	0.1716
Chronic Pulmonary Disease		753	8118	0.91	0.84—0.99	0.0269
Congestive Heart Failure		72	723	1.00	0.78—1.27	0.9729
Coronary Artery Disease		276	3156	0.87	0.76—0.98	0.026
Depression		1138	12,586	0.87	0.81—0.93	0.0001
Peripheral Vascular Disease		241	2488	0.97	0.84—1.11	0.6257

The number of patients within each age group were compared between cohorts using odds ratios and 95% confidence intervals. To compare rates of baseline medical comorbidities between cohorts, the number of patients diagnosed with each medical comorbidity prior to undergoing primary THA were also compared using odds ratios and 95% confidence intervals